Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of vornorexant in Japanese adults with insomnia disorder
jRCT2031220209Phase 3Completed
- Sponsor
- Taisho Pharmaceutical
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vornorexant in Insomnia (3 arms), sponsored by Taisho Pharmaceutical. Primary endpoint: Change from baseline in subjective sleep latency. Started Aug 2022; status: completed.
02
Drugs
vornorexant
03
Conditions
Insomnia
Beyond the preview
Go deeper on jRCT2031220209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220209.